Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
2005/01/04 by Edgar R. Miller, Roberto Pastor‐Barriuso, Roberto Pastor-Barriuso +5 · 38 citations
Medicine · Nursing · Biochemistry, Genetics and Molecular Biology · #Antioxidant Activity and Oxidative Stress #Vitamin C and Antioxidants Research #Retinoids in leukemia and cellular processes
paper · doi:10.7326/0003-4819-142-1-200501040-00110
Abstract
BACKGROUND: Experimental models and observational studies suggest that vitamin E supplementation may prevent cardiovascular disease and cancer. However, several trials of high-dosage vitamin E supplementation showed non-statistically significant increases in total mortality. PURPOSE: To perform a meta-analysis of the dose-response relationship between vitamin E supplementation and total mortality by using data from randomized, controlled trials. PATIENTS: 135,967 participants in 19 clinical trials. Of these trials, 9 tested vitamin E alone and 10 tested vitamin E combined with other vitamins or minerals. The dosages of vitamin E ranged from 16.5 to 2000 IU/d (median, 400 IU/d). DATA SOURCES: PubMed search from 1966 through August 2004, complemented by a search of the Cochrane Clinical Trials Database and review of citations of published reviews and meta-analyses. No language restrictions were applied. DATA EXTRACTION: 3 investigators independently abstracted study reports. The investigators of the original publications were contacted if required information was not available. DATA SYNTHESIS: 9 of 11 trials testing high-dosage vitamin E (> or =400 IU/d) showed increased risk (risk difference > 0) for all-cause mortality in comparisons of vitamin E versus control. The pooled all-cause mortality risk difference in high-dosage vitamin E trials was 39 per 10,000 persons (95% CI, 3 to 74 per 10,000 persons; P = 0.035). For low-dosage vitamin E trials, the risk difference was -16 per 10,000 persons (CI, -41 to 10 per 10,000 persons; P > 0.2). A dose-response analysis showed a statistically significant relationship between vitamin E dosage and all-cause mortality, with increased risk of dosages greater than 150 IU/d. LIMITATIONS: High-dosage (> or =400 IU/d) trials were often small and were performed in patients with chronic diseases. The generalizability of the findings to healthy adults is uncertain. Precise estimation of the threshold at which risk increases is difficult. CONCLUSION: High-dosage (> or =400 IU/d) vitamin E supplements may increase all-cause mortality and should be avoided.
Cited by
- Antioxidants for Alzheimer Disease
- ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
- 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association
- Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
- Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
- Current Pharmacotherapy for Alzheimer's Disease
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications
- Free radicals and antioxidants in normal physiological functions and human disease
- Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?
- Iron Behaving Badly: Inappropriate Iron Chelation as a Major Contributor to the Aetiology of Vascular and Other Progressive Inflammatory and Degenerative Diseases
- Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane
- Antioxidant [wikipedia]
- Tocotrienols: Vitamin E beyond tocopherols. [europepmc]
- 100 years and counting: prospects for defeating Alzheimer's disease. [europepmc]
- A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. [europepmc]
- 25-hydroxyvitamin D levels and the risk of mortality in the general population. [europepmc]
- Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. [europepmc]
- Age-related macular degeneration. [europepmc]
- Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). [europepmc]
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. [europepmc]
- Reactive oxygen species in the regulation of synaptic plasticity and memory. [europepmc]
- Vitamins C and E: beneficial effects from a mechanistic perspective. [europepmc]
- Components of a cardioprotective diet: new insights. [europepmc]
- Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. [europepmc]
- Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. [europepmc]
- Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. [europepmc]
- Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. [europepmc]
- Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. [europepmc]
- Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. [europepmc]
- Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? [europepmc]
- Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. [europepmc]
- Current and future pharmacological therapies for NAFLD/NASH. [europepmc]
- Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. [europepmc]
- ESPEN guideline on clinical nutrition in liver disease. [europepmc]
- Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. [europepmc]
- Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. [europepmc]
- NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. [europepmc]
Related